Sunny Pharmtech Inc.’s CPA-I successfully dispatched its inaugural shipment on 30th November

撰文GlobalBio & Investment
日期2023-12-31
EnglishFrenchGermanItalianPortugueseRussianSpanish
Sunny Pharmtech Inc.’s CPA-I successfully dispatched its inaugural shipment on 30th November
Sunny Pharmtech Inc. 祥翊製藥股份有限公司’s generic drug injectable, Cyclophosphamide (CPA-I), successfully dispatched its inaugural shipment on 30th November, targeting a $100 million market. This FDA-approved CPA-I, granted in late October, is used in treating various types of cancers. 

Dive deeper: https://lnkd.in/dk3gT_D7
Stay tuned to #Globalbio on LinkedIn for the latest updates!

#SunnyPharmtech #FDAapproval #GenericDrugs #cancertreatment

GlobalBio & Investment

Go Global and Beyond:
A Premier Biomedical Media in Taiwan
下一篇
Dr. Hsing-Pang Hsieh, Director of IBPR at NHRI is elected to the National Academy of Inventors

TOP
  • Global Bio and Investment Monthly
  • 讀者服務電話：+886 2 2726 1065時間：週一 ~ 週五 09:00 ~ 18:00
  • 服務信箱：[email protected]
  • 地址：110臺北市信義區信義路六段29號2樓之一, Taiwan

我們的服務